|
|
||||||||
2-adrenergic receptors by
epinephrine during exercise in human adipose tissue
1 Department of Sport Medicine,
Third Faculty of Medicine, Charles University, 100 00 Praha, Czech
Republic; 4 Laboratory of Medical
and Clinical Pharmacology, The involvement of the antilipolytic
lipolysis; microdialysis; norepinephrine; glycerol; insulin; blood
flow
several lines of evidence support the view that, during
exercise, increased sympathetic nervous system (SNS) activity is
responsible for the increase in lipid mobilization, since
catecholamines are of major importance for the regulation of lipolysis
in adipose tissue (AT; see Refs. 21 and 30) and for the increase of
nonesterified fatty acid (NEFA) supply to the working muscle (7, 8,
17). During prolonged exercise, it is probable that other mechanisms reinforce the SNS-induced activation of lipolysis. They probably include a decrease of insulin, an increase in growth hormone and cortisol, and also a rise in plasma epinephrine (11, 14, 24). The
specific role of these factors, particularly of epinephrine, in lipid
mobilization during exercise is thus difficult to establish.
The coexistence of The aim of the present study was to examine the influence of
epinephrine lipolysis through the
The present results showed that the higher exercise-induced epinephrine
concentration in plasma during the second exercise promoted increased
lipid mobilization as shown by an increase in plasma glycerol and NEFA
concentrations and in extracellular glycerol concentration (measured
with the microdialysis method). It was shown that glycerol output in
subcutaneous AT was enhanced by the blockade of Subjects
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
2-adrenergic pathway and the
specific role of epinephrine in the control of lipolysis during
exercise in adipose tissue (AT) were investigated in healthy male
subjects (age: 24.1 ± 2.2 yr; body mass index: 23.0 ± 1.6). An
in vitro study carried out on isolated adipocytes showed that the weak
lipolytic effect of epinephrine was potentiated after blockade of
2-adrenergic receptor (AR) by
an
2-AR antagonist and reached
that of isoproterenol, a
-AR agonist. The effect of the nonselective
2-AR antagonist phentolamine on
the response of the extracellular glycerol concentration (EGC) in AT
during two successive bouts of aerobic exercise (50% maximum
O2 uptake, 60 min duration) was
evaluated using the microdialysis method. The metabolic responses
measured in perfused probes with Ringer solution were compared with
those obtained in perfused probes with Ringer plus 0.1 mmol/l
phentolamine. Plasma norepinephrine level was not different during the
two exercise bouts, whereas that of epinephrine was 2.5-fold higher
during the second exercise. EGC in AT was twofold higher in the second
compared with the first exercise, and the same response pattern was
found for plasma glycerol. The exercise-induced increase in EGC was
higher in the probe perfused with phentolamine compared with the
control probe in both bouts of exercise. However, the potentiating
effect of phentolamine on EGC was significant during the second
exercise bout but did not reach a significant level during the first.
These results suggest that epinephrine is involved in the control of
lipid mobilization through activation of antilipolytic
2-AR in human subcutaneous AT
during exercise.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-adrenergic receptors (AR) that increase and
2-AR that decrease the rate of
lipolysis in human fat cells still raises questions about their
physiological relevance. The presence of
- and
2-ARs has clearly been
demonstrated by functional in vitro assays in isolated human fat cells
and binding studies with selective ligands (9, 28, 30, 31). In human
fat cells, where
2-AR outnumber
-AR, the preferential recruitment of the
2-AR, leading to an inhibition
of lipolysis at lower catecholamine concentrations (10, 33), has been
described in vitro. In addition, it has been shown that epinephrine is
the amine with the highest affinity for fat cell
2-ARs (29).
-AR-stimulated
lipolysis occurs at the highest concentrations of the amines. This dual effect of catecholamines on isolated human fat cells (i.e.,
antilipolytic and then lipolytic according to the concentration of the
amine) was particularly striking in femoral adipocytes from overweight women (33) and was also observed in subcutaneous adipocytes from obese
men (32). The physiological relevance of such in vitro responsiveness
to catecholamines remains in doubt. Microdialysis appears to be an
alternative method to study the lipolytic responses of AT in vivo to
pharmacological drugs (2, 40) or during exercise (1, 11, 18). Although
approaches based on the utilization of the microdialysis method have
become considerably more numerous during the last years, studies
concerning the action of the physiological amines (epinephrine and
norepinephrine) toward
- or
2-adrenoceptor-mediated
pathways in human subcutaneous AT have been scarcely reported.
2-adrenergic pathway during exercise. For that, healthy male subjects, fasted overnight, performed two bouts of prolonged exercise [60 min, 50% maximum
O2 uptake (
O2 max)]
separated by an equivalent period of rest. The model of the repeated
exercise was selected because the two bouts are characterized by the
same increase in plasma norepinephrine levels but different epinephrine
responses (personal data), and thus the comparison of the responses to
the two bouts provides an opportunity to discriminate, in physiological
conditions, between the actions of the two catecholamines.
-AR by phentolamine
and that there was a relationship between the epinephrine levels and
magnitude of the enhancement, i.e., the enhancement was higher during
the second exercise when epinephrine levels increased more.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
O2 max and heart rate
were determined on an electrically braked bicycle ergometer
(Ergometrics 800s; Ergoline, Jaeger, Germany) by use of an incremental
procedure (work rate increasing by 15 W/min) for the subjects that
participated in the dialysis protocol. The rate of
O2 consumption
(
O2) was measured using a
maximal velocity
(Vmax)
apparatus (Sensor Medics, Yorba Linda, CA), and the highest
O2 value was considered as
O2 max. The mean
O2 max was
46.4 ± 5.3 ml
O2 · kg
1 · min
1
(range: 40.8-56.2 ml
O2 · kg
1 · min
1).
All subjects had given their informed consent before the study. The
studies were performed according to the Declaration of Helsinki and
were approved by the Ethical Committee of Prague, Faculty of Medicine
(University Hospital).
In Vitro Lipolysis Measurements
A biopsy of abdominal subcutaneous AT was performed (after intradermal anesthesia with 1% lidocaine; Roger-Bellon, Neuilly-s-Seine, France) with a 2.3-mm-diameter needle. By successive suctions, ~200-300 mg of AT were drawn into a syringe. Biopsies were made between 8 and 9 AM after an overnight fast. Adipocytes were quickly isolated using the method previously described (4, 10) in a Krebs-Ringer bicarbonate-HEPES solution (pH = 7.4) containing 2% BSA, 6 mmol/l glucose (KRBHA), and 0.5 mg/ml collagenase. Isolated adipocytes were washed three times, and the cells were used for lipolysis measurements in KRBHA buffer. Concentration-response curves were obtained using isoproterenol (a nonselective
-AR agonist) and epinephrine alone or in the presence
of 10 µmol/l RX-82,1002 (a selective
2-AR antagonist). All
pharmacological compounds were added to a 5-µl volume at the start of
the incubation performed with 2,000-3,000 isolated fat cells in a
final volume of 100 µl KRBHA. The incubation was run for 90 min, and
30 µl of infranatant were removed for the determination of glycerol (lipolytic index). Lipolytic activity was expressed as micromoles of
glycerol released per milligram lipid for 90 min.
In Vivo Experimental Protocols
The subjects were investigated at 8 AM after an overnight fast and were placed in a semirecumbent position. Two microdialysis probes (Carnegie Medecin, Stockholm, Sweden) of 20 × 0.5 mm and 20,000-molecular weight cutoff were inserted percutaneously after epidermal anesthesia (200 µl of 1% lidocaine; Roger-Bellon) into the abdominal subcutaneous AT at a distance of 10 cm immediately to the right of the umbilicus. The probes were separated by 5 cm and were connected to a microinjection pump (Harvard apparatus; SARL, Les Ulis, France). One probe (A) was perfused with Ringer solution (139 mmol/l sodium, 2.7 mmol/l potassium, 0.9 mmol/l calcium, 140.5 mmol/l chloride), and the second (B) was infused with Ringer plus 0.1 mmol/l phentolamine (
-AR antagonist). This nonselective
1-/
2-antagonist
is the only agent allowed in microdialysis assays in humans. The two
perfusate solutions were supplemented with ethanol (1.7 g/l). Ethanol
was added to the perfusate to estimate changes in the blood flow, as
previously described (2, 3, 13, 20). After a 30-min equilibration
period, a 30-min fraction of dialysate was then collected at a flow
rate of 0.5 µl/min. Next, the perfusion was set at 2.5 µl/min for
the remaining experimental period. The calibration procedure using
various perfusion rates was applied for interstitial glycerol
concentration in AT and was previously described by our group (2, 3,
13, 34). This time-consuming method was not used in this study. A
simplified technique was used. The estimated extracellular glycerol
concentrations were calculated by plotting (after log transformation)
the concentration of glycerol in the dialysate measured at 0.5 and 2.5 µl/min against the perfusion rates. The values of extracellular
glycerol concentrations found in the present study fit with previous
determinations in lean subjects (2, 22, 23, 34).
After the calibration of the probes, the subjects performed an exercise
for 60 min with an imposed power corresponding to 50% of their
O2 max on the cycle
ergometer. The heart rate was continuously monitored with a Baumann BHL
6000 cardiometer during the exercise.
O2 was measured regularly
using a Vmax
apparatus (Sensor Medics). Next, the subjects were allowed to rest in
the semirecumbent position for 60 min, after which they performed a new
60-min exercise with an imposed power such that their heart rate was
kept constant and similar to that recorded during the first exercise
bout. Finally, the subjects rested again for 60 min. Water intake was
allowed ad libitum during the exercise and recovery periods.
During the whole experimental period, including resting periods, 15-min
fractions of dialysate were collected from the probes. At the
corresponding times (i.e., every 15 min), 5 ml of blood were collected
from an indwelling polyethylene catheter inserted into an antecubital
vein. The catheter was kept patent by slow infusion of saline. Blood
was collected on 50 µl of an anticoagulant and antioxidant cocktail
(Immunotech, Marseille, France) to prevent oxidation of catecholamines
and was immediately spun down in a refrigerated
centrifuge. The plasma was stored at
80°C until analysis.
Drugs and Biochemical Determinations
Isoproterenol hydrochloride (Isuprel) and phentolamine methanesulfonic acid (Regitine) were obtained from Sterling Winthrop (Clichy, France) and Giba-Geigy (Reuil-Malmaison, France), respectively. RX-82,1002 [2-(2-methoxy-1,4-benzodioxan-2yl)-2-imidazoline] was a generous gift of Reckitt & Colman Laboratories (Kingston-upon-Hull, UK). Glycerol in dialysate (10 µl) and in plasma (20 µl) was analyzed with an ultrasensitive radiometric method (6), and the intra-assay and interassay variabilities were 5.0 and 9.2%, respectively. Ethanol in dialysate and perfusate (5 µl) was determined with an enzymatic method (5), and the intra-assay and interassay variabilities were 3.0 and 4.5%, respectively. Plasma glucose and NEFA were determined with a glucose oxidase technique (Biotrol kit; Merck-Clevenot, Nogent-s-Marne, France) and an enzymatic procedure (Wako kit; Unipath, Dardilly, France), respectively. Plasma insulin concentrations were measured using RIA kits from Sanofi Diagnostics Pasteur (Marnes la Coquette, France). Plasma epinephrine and norepinephrine were assayed in 1-ml aliquots of plasma by high-pressure liquid chromatography using electrochemical (amperometric) detection (11). The detection limit was 20 pg/sample. Day-to-day variability was 4%, and within-run variability was 3%.Statistical Analysis
All the values are means ± SE. The responses to exercise were analyzed using a paired t-test and ANOVA, when appropriate. During exercise, plasma and extracellular concentration-response curves were calculated as the total integrated changes over baseline values [area under the curve (AUC) from time (t) = 0 to t = 60 min and t = 120 to t = 180 min]. AUC were calculated using a trapezoidal method. Significant values are quoted in Figs. 1-4 and in Table 1. P < 0.05 was considered statistically significant.| |
RESULTS |
|---|
|
|
|---|
In Vitro Results
In vitro assays were performed to assess the existence of an
2-adrenergic component in the
regulation of lipolysis in the subjects. Concentration-response curves
of glycerol release from isolated fat cells obtained with
isoproterenol, epinephrine alone, and epinephrine in the presence of
the selective
2-AR antagonist (RX-82,1002) are depicted in Table 1. A
significant lipolytic effect of isoproterenol (a
-AR agonist) was
observed with 0.01 µmol/l, the maximal effect being reached with 0.1 µmol/l. Epinephrine was devoid of lipolytic effect until 1 µmol/l,
and a significant increase in glycerol production was observed only
with 10 µmo/l. A clear increase in the lipolytic effect of
epinephrine was observed when RX-82,1002 was added to the incubation
medium. Epinephrine-induced glycerol release was significant with 0.1 µmol/l, and the maximal effect (obtained with 1 µmol/l epinephrine)
was similar to that of isoproterenol.
|
In Vivo Results
General observations. Perceived exertion was not augmented by the second bout of exercise by the subjects. The power developed was regularly adjusted to maintain the heart rate constant over each exercise bout. Values of heart rate and
O2 measured during the last 5 min of each exercise period, i.e., t = 55-60 min and 175-180 min, were 136 ± 3 and 141 ± 4 beats/min (not significant) and 1.45 ± 0.07 and 1.33 ± 0.05 l/min (not significant), respectively. The power developed during the
second exercise bout was significantly lower (102 ± 7 and 85 ± 6 W, respectively).
Plasma catecholamine
concentrations. At rest, plasma
norepinephrine and epinephrine concentrations were 192 ± 38 and 59 ± 21 pg/ml, respectively (Fig. 1).
Half-way through the period of exercise
(t = 30 min), the plasma
norepinephrine concentration rose (482% of the basal values) and did
not change significantly (551%) until the end of exercise
(t = 60 min). At the end of the recovery period (t = 120 min),
norepinephrine concentration decreased to a value (227 ± 36 pg/ml)
that did not differ from that measured in basal conditions
(t = 0 min). No differences were found
in the time course of plasma norepinephrine concentration increment during the second bout of exercise. The increments were 463 and 557%
at 150 and 180 min, respectively, and were no different
(P = 0.54) from that measured during
the first exercise bout. The plasma epinephrine concentration rose to
147% of the basal values after 30 min of exercise and rose
progressively (P = 0.01) until the end
of exercise (271%). During recovery, the epinephrine concentration decreased to a value that did not differ at
t = 120 min (61 ± 20 pg/ml) from
that measured in basal conditions (t = 0 min). During the second exercise bout, the plasma epinephrine
concentrations (measured at t = 150 and 180 min) dramatically rose to values significantly higher than
those measured during the first bout of exercise. The corresponding
increments were 236 and 496% at t = 150 and 180 min, respectively. The AUC calculated for the norepinephrine and epinephrine increase in plasma during the second exercise bouts showed significantly higher values for epinephrine (6,637 ± 960 vs. 2,586 ± 526 pg · ml
1 · 60 min
1;
P = 0.001) but not for norepinephrine
(38,261 ± 4.380 vs. 32,236 ± 4,501 pg · ml
1 · 60 min
1).
|
Plasma glucose and insulin
concentrations. In the baseline period, the plasma
concentrations of glucose and insulin were 4.3 ± 0.1 mmol/l and 3.7 ± 0.7 µU/ml, respectively (Fig. 2).
No significant variation of plasma glucose level was observed during
the first exercise. A significant decrease in plasma glucose
concentration was observed at the end of the second exercise and during
the second recovery period. Plasma insulin concentration tended to decrease during the first exercise bout. However, due to large interindividual variations, the decrease was only significant after 60 min of exercise. During the second bout of exercise, plasma insulin
concentrations significantly decreased starting from 15 min of exercise
and continued to decrease steadily until the end of the exercise
period. During the second bout of exercise, plasma insulin
concentrations were lower than those measured at the corresponding
times during the first bout of exercise. The AUC calculated for insulin
variations in plasma during the second exercise bouts showed
significantly higher values (82 ± 28 vs. 31 ± 9 µU · ml
1 · 60 min
1;
P = 0.01).
|
Plasma NEFA and glycerol levels and extracellular
glycerol concentration in AT. During the baseline
period, plasma glycerol and NEFA concentrations were 52 ± 5 and 337 ± 41 µmol/l, respectively (Fig.
3). The corresponding baseline
extracellular glycerol concentrations in subcutaneous AT were not
significantly different in probe A infused with Ringer alone (185 ± 35 µmol/l) and
probe B infused with phentolamine (229 ± 28 µmol/l).
|
Plasma NEFA concentrations were unchanged all along the first exercise period. After 15 min of recovery, NEFA concentration increased significantly and then decreased to values different from those found in basal conditions at t = 0 min. During the second exercise bout, plasma NEFA concentration increased significantly starting from 15 min and gradually rose during the exercise period (Fig. 3A).
Starting from 30 min into the first exercise, the extracellular
glycerol concentration increased significantly in
probe A. Plasma glycerol increased
significantly 15 min after the beginning of exercise. Next, both the
plasma and extracellular glycerol concentrations steadily increased. At
the end of exercise, the increases were ~125 and 172% in plasma and
the extracellular compartment, respectively. The extracellular glycerol
concentration (calculated from probe B
where phentolamine was added) increased significantly starting from 15 min during the exercise. At the end of the exercise, the increase was
~235%. Although the extracellular glycerol concentration was higher
in probe B, no significant difference
was found when compared with values obtained with
probe A (calculated AUC are 16,956 ± 5,566 vs. 9,448 ± 2,428 µmol · l
1 · 60 min
1;
P = 0.07). During the recovery period,
plasma glycerol concentration (66 ± 6 µmol/l), as well as extracellular glycerol concentrations calculated from probes A and
B (209 ± 66 and 223 ± 28 µmol/l, respectively), fell
steadily to reach a level at t = 120 min not different from
that measured before exercise (t = 0 min).
During the second bout of exercise, the glycerol concentration in
plasma and the extracellular compartment calculated from probe A rose significantly starting
from 15 min of exercise and continued to rise during the exercising
period. A significant increase in glycerol concentrations in plasma and
in the extracellular compartment was observed when compared with the
glycerol increment measured during the first exercise bout. At the end
of exercise, the percentage increase was ~360 and 464% in plasma and
in the extracellular compartment, respectively. A similar qualitative response was obtained when considering probe
B, which was infused with phentolamine (Fig.
3B). The glycerol concentration in
the extracellular compartment increased significantly from 15 min into
the second exercise, and a significant increase of extracellular glycerol concentrations was observed when compared with the glycerol increment measured during the first exercise bout. However, the addition of phentolamine in probe B
significantly increased extracellular glycerol concentrations when
compared with the glycerol increment measured in control
probe A and during the second exercise
bout (calculated AUC are 33,911 ± 9,182 vs. 16,304 ± 3,030 µmol · l
1 · 60 min
1;
P = 0.03).
Ethanol outflow-to-inflow ratio in AT.
Ethanol outflow-to-inflow ratios (expressed as a percentage, i.e., the
ethanol concentration measured in the dialysate/the ethanol
concentration measured in the perfusate × 100) in the dialysate
from probes A and
B are depicted in Fig.
4. In the two resting periods
(t = 0 and 120 min), the ethanol
outflow-to-inflow ratio did not differ between probe
A (59.4 ± 3.0 and 60.1 ± 3.0, respectively) and
probe B (54.3 ± 2.7 and 55.8 ± 2.9, respectively). No significant variation of the ethanol
outflow-to-inflow ratio was observed either during the first or the
second exercise session in probe A. In
probe B, the ethanol outflow-to-inflow
ratio decreased during the two exercise bouts, with the magnitude of
the decrease being similar in the two bouts.
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study reveals that epinephrine contributes to
exercise-induced lipolysis, although the existence of
2-AR-mediated counteraction was
clearly revealed with our protocol. The coexistence of lipolytic
-ARs and antilipolytic
2-ARs
in human fat cells has been largely demonstrated through in vitro
studies on isolated fat cells and binding studies (30, 31). The rate of
lipolysis, through activation or inhibition of the adenylyl cyclase, is
relevant from this dual action of catecholamines on lipolysis (30, 31). In human subcutaneous fat cells in which
2-ARs numerically predominate over
-ARs (33), the recruitment of the
2-ARs, leading to epinephrine inhibition of lipolysis, has been described in vitro. Epinephrine is
the preferential amine for fat cell
2-adrenoceptors, suggesting that it is probably involved more than norepinephrine in the control of
lipolysis through the
2-adrenergic pathway (29). The
physiological relevance of such in vitro
2-AR responsiveness to
catecholamines is not clearly understood. Previous studies using
microdialysis have led to conflicting results. Using local
administration of phentolamine, one study has shown that resting
lipolysis was modulated by
2-adrenergic inhibition,
whereas the
2-adrenergic
mechanism did not modulate lipolysis during exercise (1). On the
contrary, Hellström et al. (18) showed that phentolamine
potentiated exercise-induced lipolysis in men (but not in women).
However, in these studies, the contribution of epinephrine to the
lipolytic responses to
2-adrenergic blockade was not assessed.
The first part of the present study, carried out in vitro, demonstrated
the effect of the blockade of
2-ARs on epinephrine-induced lipolysis in the fat cells from healthy young subjects used in the
present study. Two points arise from these results. First, they
demonstrate the relative effect of catecholamines on
2- and
-ARs, and the results
fit with previously reported in vitro observation demonstrating that
epinephrine has a higher affinity for
2-AR than for
-ARs (29).
Epinephrine had no lipolytic effect on fat cells below concentrations
of 1 µmol/l, whereas a lipolytic action of isoproterenol (a
nonselective
-AR agonist) was obtained with 0.01 µmol/l. The
lipolytic action of epinephrine was enhanced after blockade of
2-ARs. These in vitro findings demonstrate that the control of lipolysis through the dual action of
catecholamines on
- and
2-ARs is operational in fat
cells from young healthy subjects and in older and/or obese subjects (32, 33). They also justify research into the involvement of
2-ARs, and particularly the
role of epinephrine, in the control of lipolysis in vivo in young male subjects.
Exercise is a physiological stimulus for the activation of both the SNS and the adrenal medulla. The challenge of the experiment was to find exercise conditions inducing similar activation of the SNS and a different secretion of epinephrine. For that, an experimental protocol using two successive repeated exercise bouts, separated by an appropriate resting period, in fasting subjects was used. Determining the appropriate conditions of the two exercise bouts (intensity, duration, and recovery period) was the object of preliminary investigations.
Previous studies (26) have shown that successive exercise bouts (50%
O2 max, 30 min)
separated by 30-min resting periods progressively increased
O2, heart rate, and body
temperature. To avoid such a drift in responses, in our study, the
second exercise bout was performed with a
O2 intensity similar to that
measured during the first exercise.
O2 was not different in the
two bouts of exercise, indicating that the two bouts were performed at
identical relative intensities. The same relative intensity of the two
exercise bouts was a condition enabling the comparison of the hormonal response to each bout, because it was shown that the hormonal response
to exercise is determined by the relative rather than absolute
intensity of exercise (15, 25). It is noticeable that, in these
conditions, the power developed during the second exercise was
significantly lower than that measured during the first bout.
Hence, the activation of the SNS (assessed by plasma norepinephrine
levels) was of similar amplitude during the two exercise bouts, whereas
the second exercise led to a higher activation of the adrenal medulla
(assessed by plasma epinephrine levels). In fact, the enhanced
exercise-induced increase in plasma epinephrine levels during the
second exercise bout might be caused by the decrease in plasma glucose
level (15) occurring in the second but not in the first exercise bout.
Plasma glycerol and NEFA concentrations were higher during the second
exercise bout, showing an enhancement of lipolysis in the AT. This
enhanced lipolysis could be the direct consequence of the more
pronounced epinephrine secretion. However, the exercise-induced
reduction in plasma insulin concentration was also enhanced during the
second exercise bout. It is well known that plasma insulin
concentration decreases during exercise (21), reflecting the
adrenergic-dependent inhibition of insulin secretion through activation
of
2-AR located on the
pancreatic
-cells (35). Epinephrine is the most efficient agonist
for pancreatic
2-ARs (35). Thus
the greater decrease in plasma insulin levels observed during the
second bout of exercise, associated with the higher plasma epinephrine
concentrations, could explain the observed higher lipolytic rate. There
is no demonstration that a decrease of glucose uptake by fat cells
leads to hormone-sensitive lipase activation and increased lipolysis.
Concerning local lipolytic responses in the subcutaneous AT (assessed
by extracellular glycerol concentration), striking differences appeared
in extracellular glycerol concentration in the presence of the
-AR
antagonist phentolamine (Fig. 3). Extracellular glycerol concentration
in AT (calculated from control probe
A) was higher during the second exercise bout,
suggesting an enhancement of the lipolytic rate in this tissue. This
increased lipolytic response could be attributable to the higher plasma
epinephrine levels observed during the second exercise, which reached
the subcutaneous AT. Stallknecht et al. (37, 39) showed that, when
epinephrine is infused intravenously in humans at doses giving plasma
concentrations quite similar to those seen during exercise, its
extracellular concentration in abdominal subcutaneous AT (evaluated by
microdialysis) varies in parallel with the concentration measured in
the plasma. Interestingly, one of the main results of our study is the
finding that local
-adrenergic blockade enhances the glycerol output from AT (calculated from probe B
perfused with phentolamine). This effect did not reach a significant
level during the first exercise bout but was significant during the
second. Plasma epinephrine concentrations were twofold higher during
the second exercise than during the first, whereas the exercise-induced
increase in plasma norepinephrine levels was similar. Thus the
increased extracellular glycerol concentration in the presence of
phentolamine could be due to the local suppression of the
2-adrenergic antilipolytic component of epinephrine on fat cells.
Local blood flow has been shown to influence glycerol levels in AT (12,
16). During exercise, the increase in extracellular glycerol
concentration could be due to changes in blood flow in the AT. The
measurement of ethanol escape through the dialysis probe is a validated
nonquantitative method to estimate the changes in vascular tone in AT
(2, 3, 16). In agreement with others (18, 36), the stability of the
ethanol outflow-to-inflow ratio found in probe
A during the two exercise bouts indicated that vascular
tone was not changed during the exercise. It has previously been
demonstrated that
-AR stimulation increases and that
-AR stimulation decreases local blood flow in AT (2, 3, 16, 27, 34),
whereas insulin (at various plasma levels realized by a multistage
euglycemic hyperinsulinemic clamp) does not modify the local blood flow
in AT (38). When the
-ARs were blocked by phentolamine
(probe B), the exercise-induced
decrease in the outflow-to-inflow ratio suggests an increase in blood
flow in AT probably due to the
-adrenergic vasodilating component of catecholamine after
-AR blockade. It is a situation that could diminish glycerol output in the probes. Nevertheless, as shown in Fig.
4, the exercise-induced decrease in ethanol outflow/inflow was of
similar amplitude during the two exercise bouts in the probe perfused
with phentolamine. This suggests that the increase of interstitial
glycerol in probe B (with
phentolamine) was influenced in the same manner during the two exercise
bouts and that the
-AR-induced vasodilation is quite similar in both
conditions. Consequently, the higher response observed during the
second exercise bout indicates an enhancement of
-adrenergically
mediated lipolysis in AT, which is unmasked after blockade of
2-ARs. The disinhibition of
lipolysis after
2-adrenergic
blockade was higher during the second bout of exercise, i.e., in the
situation of higher epinephrine levels. This suggests that epinephrine
is the hormone responsible for the
2-mediated antilipolytic action
during exercise.
Our study demonstrates the physiological relevance of
- and
2-AR interplay in the control
of lipolysis in subcutaneous AT, during exercise in humans. The
exercise-induced lipolysis has been shown to be specific in respect to
region and gender (1, 18). Therefore, it is important to note that the
results of the present study are specific for male subjects and for the
subcutaneous abdominal region. The study suggests for the first time
that epinephrine has a specific role in vivo in the control of
lipolysis in human subcutaneous AT through activation of antilipolytic
2-ARs. It also updates numerous
former in vitro studies that propose that the activation of
2-ARs by epinephrine could play
an important role in the control of lipolysis in AT, specially in
abdominal subcutaneous fat deposits (33, 19). If abdominal subcutaneous fat reflects what goes in the intra-abdominal fat, as proposed by some
authors, it would be of interest to study the involvement and the
importance of the epinephrine-induced
- vs.
2-AR activation in AT in obese
subjects during exercise. The activation of antilipolytic
2-ARs by epinephrine could be
an important inhibitory factor for lipid mobilization in subcutaneous
AT in exercising obese subjects, the AT of which expresses a higher
2-AR component in vitro (32).
This should be the subject of our forthcoming studies.
| |
ACKNOWLEDGEMENTS |
|---|
We express gratitude to Marie-Thérèse Canal and Suzana Parizkova for contribution to the study. We are also indebted to Ghislaine Portolan and Marie-Antoinette Tran for laboratory support in catecholamine measurements.
| |
FOOTNOTES |
|---|
The study was partially supported by Grant GAUK 188 of the Charles University, Czech Republic, and the laboratories involved in the study participated in the FATLINK concerted action supported by the European Commission. Part of this study was carried out in collaboration with the Clinical Investigation Center of Toulouse, Purpans Hospital.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: M. Berlan, INSERM U 317, Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées Jules Guesde, 31073 Toulouse cedex, France (E-mail address: berlan{at}cict.fr).
Received 29 January 1999; accepted in final form 3 June 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Arner, P.,
E. Kriegholm,
P. Engfeldt,
and
J. Bolinder.
Adrenergic regulation of lipolysis in situ at rest and during exercise.
J. Clin. Invest.
85:
893-898,
1990.
2.
Barbe, P.,
L. Millet,
J. Galitzky,
M. Lafontan,
and
M. Berlan.
In situ assessment of the role of the
1-,
2- and
3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue.
Br. J. Pharmacol.
117:
907-913,
1996[Medline].
3.
Barbe, P.,
V. Stich,
J. Galitzky,
M. Kunesova,
V. Hainer,
M. Lafontan,
and
M. Berlan.
In vivo increase in
-adrenergic lipolytic response in subcutaneous adipose tissue of obese subjects submitted to a hypocaloric diet.
J. Clin. Endocrinol. Metab.
82:
63-69,
1997
4.
Berlan, M.,
and
M. Lafontan.
Evidence that epinephrine acts preferentially as an antilipolytic agent in abdominal human subcutaneous fat cells: assesment by analysis of beta and alpha2 adrenoceptor properties.
Eur. J. Clin. Invest.
15:
341-348,
1985[Medline].
5.
Bernst, E.,
and
I. Gutmann.
Determination of ethanol with alcohol dehydrogenase and NAD.
In: Methods of Enzymatic Analysis, edited by B. Hu. Ney York: Verlag Weinheim, 1974, p. 1499-1505.
6.
Bradley, D. C.,
and
H. R. Kaslow.
Radiometric assays for glycerol, glucose and glycogen.
Anal. Biochem.
180:
11-16,
1989[Medline].
7.
Bülow, J.
Lipid mobilization and utilization.
In: Principles of Exercise Biochemistry (2nd ed.), edited by J. R. Poortmans. Basel, Switzerland: Karger, 1993, p. 158-185.
8.
Christensen, N. J.,
and
H. Galbo.
Sympathetic nervous activity during exercise.
Annu. Rev. Physiol.
45:
139-153,
1983[Medline].
9.
Crampes, F.,
M. Beauville,
D. Rivière,
M. Garrigues,
and
M. Lafontan.
Lack of desensitization of catecholamine-induced lipolysis in fat cells from trained and sedentary women after physical exercise.
J. Clin. Endocrinol. Metab.
67:
1011-1017,
1988[Abstract].
10.
De Glisezinski, I.,
F. Crampes,
I. Harant,
M. Berlan,
J. Hejnova,
D. Rivière,
D. Langin,
and
V. Stich.
Endurance training changes in lipolytic responsiveness of obese adipose tissue.
Am. J. Physiol.
275 (Endocrinol. Metab. 38):
E951-E956,
1998
11.
De Glisezinski, I.,
I. Harant,
F. Crampes,
F. Trudeau,
A. Felez,
J. M. Cottet-Emard,
M. Garrigues,
and
D. Rivière.
Effect of carbohydrate ingestion on adipose tissue lipolysis during long-lasting exercise in trained men.
J. Appl. Physiol.
84:
1627-1632,
1998
12.
Enocksson, S.,
J. Nordenstrom,
J. Bolinder,
and
P. Arner.
Influence of local blood flow on glycerol levels in human adipose tissue.
Int. J. Obes.
19:
350-354,
1995.
13.
Felländer, G.,
B. Linde,
and
J. Bollinder.
Evaluation of the microdialysis ethanol technique for monitoring of subcutaneous adipose tissue blood flow in humans.
Int. J. Obes.
20:
220-226,
1996.
14.
Frayn, K.
Fat as fuel for exercice.
In: Nutrition and Fitness: Metabolic and Behavioral Aspects in Health and Disease, edited by A. P. Simopoulos,
and K. N. Pavlou. Basel: Karger, 1997, p. 46-62.
15.
Galbo, H.,
N. J. Christensen,
and
J. J. Holst.
Glucose induced decrease in glucagon and epinephrine responses to exercise in man.
J. Appl. Physiol.
42:
525-530,
1977
16.
Galitzky, J.,
M. Lafontan,
J. Nordenström,
and
P. Arner.
Role of vascular alpha2-adrenoceptors in regulating lipid mobilization from human adipose tissue.
J. Clin. Invest.
91:
1997-2003,
1993.
17.
Havel, R. J.,
A. Naimark,
and
C. F. Borchgrevink.
Turnover and rate oxidation of free fatty acid of blood plasma in man during exercise: studies during continuous infusion of plamitate-1-C14.
J. Clin. Invest.
42:
1054-1063,
1963.
18.
Hellström, M. L.,
E. Blaak,
and
E. Hagström-Toft.
Gender differences in adrenergic regulation of lipid mobilization during exercice.
Int. J. Sports Med.
17:
439-447,
1996[Medline].
19.
Hellström, M. L.,
S. Rôsner,
E. Hagström-Toft,
and
S. Reynisdottir.
Lipolytic catecholamine resistance linked to
-adrenoceptor sensitivity
a metabolic predictor of weight loss in obese subjects.
Int. J. Obes.
21:
314-320,
1997.
20.
Hickner, R. C.,
H. Rosdahl,
I. Borg,
U. Ungerstedt,
L. Jorfeldt,
and
J. Henriksson.
Ethanol may be used with the microdialysis technique to monitor blood flow changes in skeletal muscle: dialysate glucose concentration is blood flow-dependent.
Acta Physiol. Scand.
143:
355-356,
1991[Medline].
21.
Hodgetts, V.,
S. W. Coppack,
K. N. Frayn,
and
T. D. R. Hockaday.
Factors controlling fat mobilization from human subcutaneous adipose tissue during exercise.
J. Appl. Physiol.
71:
445-451,
1991
22.
Jansson, P. A.,
A. Larsson,
U. Smith,
and
P. Lönnroth.
Glycerol production in subcutaneous adipose tissue of lean and obese humans.
J. Clin. Invest.
89:
1610-1617,
1992.
23.
Jansson, P. A.,
U. Smith,
and
P. Lönnroth.
Interstitial glycerol concentration measured by microdialysis in two subcutaneous regions in humans.
Am. J. Physiol.
258 (Endocrinol. Metab. 21):
E918-E922,
1990
24.
Kempen, K. P. G.,
W. H. M. Saris,
J. M. G. Senden,
P. P. C. A. Menheere,
E. E. Blaak,
and
M. A. Van Baak.
Effect of energy restriction on acute adrenoceptor and metabolic responses to exercise in obese subjects.
Am. J. Physiol.
267 (Endocrinol. Metab. 30):
E694-E701,
1994
25.
Kjaer, M.,
N. H. Secher,
and
H. Galbo.
Physical stress and catecholamine release.
Baillieres Clin. Endocrinol. Metab.
1:
279-298,
1987[Medline].
26.
Kruk, B.,
M. Szczypaczewska,
B. Opaszowski,
H. Kaciuba-Uscilko,
and
K. Nazar.
Thermoregulatory and metabolic responses to repeated bouts of prolonged cycle-ergonometer exercise in man.
Acta Physiol. Pol.
41:
22-31,
1990[Medline].
27.
Lafontan, M.,
and
P. Arner.
Application of in situ microdialysis to measure metabolic and vascular responses in adipose tissue.
Trends Pharmacol. Sci.
17:
309-313,
1996[Medline].
28.
Lafontan, M.,
and
M. Berlan.
Evidence for
2 nature of the
-adrenergic receptor inhibiting lipolysis in human fat cells.
Eur. J. Pharmacol.
66:
87-93,
1980[Medline].
29.
Lafontan, M.,
and
M. Berlan.
Characterization of physiological agonist selectivity of human fat cell alpha2-adrenoceptors: epinephrine is the major stimulant of the alpha2-adrenoceptor.
Eur. J. Pharmacol.
82:
107-111,
1982[Medline].
30.
Lafontan, M.,
and
M. Berlan.
Fat cell adrenergic receptors and the control of white and brown fat cell function.
J. Lipid Res.
34:
1057-1091,
1993[Abstract].
31.
Lafontan, M.,
and
M. Berlan.
Fat cell
2-adrenoceptors: the regulation of fat cell function and lipolysis.
Endocr. Rev.
16:
716-738,
1995[Medline].
32.
Mauriège, P.,
J. P. Desprès,
D. Prud'Homme,
M. C. Pouliot,
M. Marcotte,
A. Tremblay,
and
C. Bouchard.
Regional variation in adipose tissue lipolysis in lean and obese men.
J. Lipid Res.
32:
1625-1633,
1991[Abstract].
33.
Mauriège, P.,
J. Galitzky,
M. Berlan,
and
M. Lafontan.
Heterogeneous distribution of beta and alpha2 adrenoceptor binding sites in human fat cells from various deposits: functional consequenses.
Eur. J. Clin. Invest.
17:
156-165,
1987[Medline].
34.
Millet, L.,
P. Barbe,
M. Lafontan,
M. Berlan,
and
J. Galitzky.
Catecholamine effects on lipolysis and blood flow in human abdominal and femoral adipose tissue.
J. Appl. Physiol.
85:
148-157,
1998
35.
Nakadate, T.,
T. Nakaki,
T. Muraki,
and
R. Kato.
Regulation of plasma insulin level by alpha-2-adrenergic receptors.
Eur. J. Pharmacol.
65:
421-424,
1980[Medline].
36.
Ranneries, C.,
J. B Low,
B. Buemann,
N. J. Christensen,
J. Madsen,
and
A. Astrup.
Fat metabolism in formerly obese women.
Am. J. Physiol.
274 (Endocrinol. Metab. 37):
E155-E161,
1998
37.
Stallknecht, B.,
J. Bülow,
E. Frandsen,
and
H. Galbo.
Desentization of human adipose tissue to adrenaline stimulation studied by microdialysis.
J. Physiol. (Lond.)
500:
271-282,
1997[Medline].
38.
Stallknecht, B.,
L. Simonsen,
and
J. Bülow.
Influence of insulin and adrenaline on blood flow in human adipose tissue.
Int. J. Obes.
2, Suppl. 3:
S17,
1998.
39.
Stallknecht, B.,
L. Simonsen,
J. Bülow,
J. Vinten,
and
H. Galbo.
Effect of training on epinephrine-stimulated lipolysis determined by microdialysis in human adipose tissue.
Am. J. Physiol.
269 (Endocrinol. Metab. 32):
E1059-E1066,
1995
40.
Stich, V.,
I. De Glisezinski,
J. Galitzky,
J. Hejnova,
F. Crampes,
D. Rivière,
and
M. Berlan.
Edurance training increases
-adrenergic lipolytic response in subcutaneous adipose tissue in obese subjects.
Int. J. Obesity.
23:
374-381,
1999.
This article has been cited by other articles:
![]() |
C. Moro, J. Polak, J. Hejnova, E. Klimcakova, F. Crampes, V. Stich, M. Lafontan, and M. Berlan Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E864 - E869. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mittendorfer, D. A. Fields, and S. Klein Excess body fat in men decreases plasma fatty acid availability and oxidation during endurance exercise Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E354 - E362. [Abstract] [Full Text] |
||||
![]() |
I. de Glisezinski, C. Moro, F. Pillard, F. Marion-Latard, I. Harant, M. Meste, M. Berlan, F. Crampes, and D. Riviere Aerobic training improves exercise-induced lipolysis in SCAT and lipid utilization in overweight men Am J Physiol Endocrinol Metab, November 1, 2003; 285(5): E984 - E990. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Philipp, M. Brede, and L. Hein Physiological significance of alpha 2-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R287 - R295. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mittendorfer, J. F. Horowitz, and S. Klein Effect of gender on lipid kinetics during endurance exercise of moderate intensity in untrained subjects Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E58 - E65. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Flechtner-Mors, C. P. Jenkinson, A. Alt, G. Adler, and H. H. Ditschuneit In Vivo alpha 1-Adrenergic Lipolytic Activity in Subcutaneous Adipose Tissue of Obese Subjects J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 229 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. De Glisezinski, F. Marion-Latard, F. Crampes, M. Berlan, J. Hejnova, J. M. Cottet-Emard, V. Stich, and D. Riviere Lack of {alpha}2-adrenergic antilipolytic effect during exercise in subcutaneous adipose tissue of trained men J Appl Physiol, October 1, 2001; 91(4): 1760 - 1765. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Marion-Latard, I. De Glisezinski, F. Crampes, M. Berlan, J. Galitzky, H. Suljkovicova, D. Riviere, and V. Stich A single bout of exercise induces {beta}-adrenergic desensitization in human adipose tissue Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2001; 280(1): R166 - R173. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Stich, I. De Glisezinski, F. Crampes, J. Hejnova, J.-M. Cottet-Emard, J. Galitzky, M. Lafontan, D. Riviere, and M. Berlan Activation of alpha 2-adrenergic receptors impairs exercise-induced lipolysis in SCAT of obese subjects Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2000; 279(2): R499 - R504. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||